亚宝药业
(600351)
| 流通市值：47.82亿 | | | 总市值：47.82亿 |
| 流通股本：6.92亿 | | | 总股本：6.92亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,144,946,503.15 | 572,022,344.93 | 2,240,063,505.22 | 1,708,712,223.13 |
| 营业收入 | 1,144,946,503.15 | 572,022,344.93 | 2,240,063,505.22 | 1,708,712,223.13 |
| 二、营业总成本 | 916,155,852.99 | 446,340,355.85 | 1,910,000,308.4 | 1,422,105,604.68 |
| 营业成本 | 526,844,821.93 | 267,453,357.65 | 1,063,788,746.1 | 817,879,312.83 |
| 税金及附加 | 17,249,358.45 | 8,204,767.23 | 34,260,998.62 | 26,599,855.66 |
| 销售费用 | 217,146,896.42 | 103,576,284.48 | 451,801,241.78 | 327,463,027.22 |
| 管理费用 | 112,269,529.47 | 49,118,006.45 | 246,054,656.52 | 180,385,376.52 |
| 研发费用 | 43,415,654.75 | 18,348,350.61 | 117,270,588.18 | 72,291,467.66 |
| 财务费用 | -770,408.03 | -360,410.57 | -3,175,922.8 | -2,513,435.21 |
| 其中:利息费用 | 414,068.3 | 187,909.54 | 1,455,727.72 | 1,097,123.49 |
| 其中:利息收入 | 1,422,289.43 | 705,047.15 | 5,013,992.33 | 3,872,574.2 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -16,308,139.15 | -14,061,111.77 | 19,004,345.09 | 1,085,508.33 |
| 加:投资收益 | 2,349,415.29 | 903,958.83 | 74,038,738.49 | 1,557,235.64 |
| 资产处置收益 | 1,530,831.53 | - | 182,987.15 | 70,086.07 |
| 资产减值损失(新) | -424,908.11 | 1,374,023.15 | -83,579,791.24 | -66,395,069.1 |
| 信用减值损失(新) | -2,630,647.25 | 303,318.85 | 8,302,156.71 | 10,487,798.34 |
| 其他收益 | 17,961,243.67 | 10,173,386.66 | 22,827,144.49 | 19,846,672.94 |
| 四、营业利润 | 231,268,446.14 | 124,375,564.8 | 370,838,777.51 | 253,258,850.67 |
| 加:营业外收入 | 1,463,936 | 433,036.01 | 7,120,275.25 | 3,289,402.95 |
| 减:营业外支出 | 3,418,828.78 | 56,021.49 | 3,501,373.58 | 3,184,289.28 |
| 五、利润总额 | 229,313,553.36 | 124,752,579.32 | 374,457,679.18 | 253,363,964.34 |
| 减:所得税费用 | 50,082,393.45 | 17,779,565.1 | 74,558,401.51 | 54,872,495.17 |
| 六、净利润 | 179,231,159.91 | 106,973,014.22 | 299,899,277.67 | 198,491,469.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 179,231,159.91 | 106,973,014.22 | 299,899,277.67 | 198,491,469.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 177,596,487.26 | 106,662,285.31 | 320,013,385.64 | 215,094,293.85 |
| 少数股东损益 | 1,634,672.65 | 310,728.91 | -20,114,107.97 | -16,602,824.68 |
| 扣除非经常损益后的净利润 | 179,283,467.83 | 111,645,838.17 | 231,571,401.19 | 197,453,009.3 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.26 | 0.15 | 0.46 | 0.31 |
| 八、其他综合收益 | 1,363,821.68 | - | -3,161,788.86 | - |
| 归属于母公司股东的其他综合收益 | 1,363,821.68 | - | -3,161,788.86 | - |
| 九、综合收益总额 | 180,594,981.59 | 106,973,014.22 | 296,737,488.81 | 198,491,469.17 |
| 归属于母公司股东的综合收益总额 | 178,960,308.94 | 106,662,285.31 | 316,851,596.78 | 215,094,293.85 |
| 归属于少数股东的综合收益总额 | 1,634,672.65 | 310,728.91 | -20,114,107.97 | -16,602,824.68 |
| 公告日期 | 2026-08-01 | 2026-04-25 | 2026-04-25 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |